Advance in the chemotherapy resistance of retinoblastoma
10.3980/j.issn.1672-5123.2023.10.10
- VernacularTitle:视网膜母细胞瘤化疗耐药的研究进展
- Author:
Yi-Lin YU
1
;
Sheng-Fang GE
1
;
Jia-Yan FAN
1
Author Information
1. Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine;Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai 200011, China
- Publication Type:Journal Article
- Keywords:
retinoblastoma;
chemotherapy resistance;
cancer therapy
- From:
International Eye Science
2023;23(10):1653-1657
- CountryChina
- Language:Chinese
-
Abstract:
Retinoblastoma(RB)is the most common intraocular malignant tumor of children. Chemotherapy is a preferred method in RB treatment, which includes intravenous chemotherapy, intra-arterial chemotherapy and intravitreal chemotherapy. However, the occurrence of chemotherapy resistance often leads to the failure of eye-preserving treatment in RB patients. Therefore, exploring the mechanism of the occurrence of chemotherapy resistance and searching for new strategies and combined medicines for RB treatment are of great clinical significance. This article reviews that RB cells obtain chemotherapy resistance through ATP binding cassette protein(ABC transporter), non-coding RNA, epigenetics modification, autophagy, epithelial mesenchymal transformation, extracellular matrix changes and other ways, and the potential therapeutic targets for chemotherapy resistance are also summarized, in the hope of providing some references for further research on chemotherapy resistance of RB.
